Which COVID-19 vaccine should I get?

Should I try and get an mRNA vaccine? They are better than the others, aren’t they? If I show up at the clinic can I choose?

 These are some of the questions that we didn’t even know we would be so lucky to ask just three months ago. 

The speed at which multiple vaccines to choose from has come about is unprecedented. 

The first genome sequence of a previously unknown virus was published in early January 2020 and the Pfizer and Moderna mRNA vaccines, tested over the summer and fall of 2020, were approved for emergency use in early December. 

These are the quickest vaccines ever developed. Their very speed has raised a lot of questions around their safety. It is true that all previous vaccines have taken years to develop and the cumulative experience of their use over time is reassuring. 

Moderate reactions

Nevertheless the COVID-19 vaccines have been tested in very big trials. As a comparison, the widely used and “uncontroversial” Shingrix vaccine for prevention of shingles was tested in 32,000 participants prior to submission for approval in 2017. The total number of patients in COVID-19 vaccine trials that have reported results so far is 170,000 and growing rapidly. 

The safety results have been reassuring — both in the trial participants and now in millions of people worldwide who have been vaccinated and reported to national monitoring systems. 

Rates of severe side effects, mainly anaphylaxis, have been very rare — a handful in every million vaccinated — and the more common reactions such as arm pain, fever, fatigue and muscle aches have been over very quickly. 

The brief discomfort of COVID-19 vaccines seems to be greater than for the annual flu shot. This probably reflects a combination of both the “prime-boost” two-shot strategy to provoke maximum stimulation of the immune system; and the large group of vaccinees who were recently infected naturally with SARS-CoV-2 and already have a naturally primed immune system ready to react. Maybe the single-shot Johnson & Johnson vaccine will have fewer reactions?

Don’t compare the numbers

There are now three vaccines available in the USA (Pfizer, Moderna and Johnson & Johnson) and several more globally, with more to come. 

Inevitable comparisons between the different vaccines, using their “headline” efficacy numbers, is a favorite media story at the moment. This has stimulated “vaccine shopping,” which has reached damaging levels in places like Germany, where the UK Astra-Zeneca vaccine sits un-used in warehouses whilst people wait, unprotected, for the Pfizer vaccine. 

The efficacy numbers attached to the two shots is responsible for this: 95% for Pfizer versus 62% for Astra-Zeneca. 

These numbers are a snapshot in time and can’t be compared with each other. 

Different vaccine trials

The Pfizer number was generated from a trial mainly in the USA, where most of the patients were recruited in the summer and fall of 2020. 

The Astra-Zeneca number was reported from a trial that included a substantial mixture of patients from the UK, South Africa and Brazil. 

The Pfizer and Moderna trials closely adhered to the three- or four-week interval between doses, whereas the Astra-Zeneca trial had a less strict timing. 

The different trials measured infection and symptoms in different ways at different time points. 

In more recent trials — for example the Johnson & Johnson and Novavax trials — there were large numbers of infections with new virus variants included as well. 

The efficacy result of each trial is reflective of the performance of the vaccine WITHIN that trial compared with a placebo — but not comparable OUTSIDE of the trial with the other vaccines.

Real-world results

To emphasize this, we have recent large-scale program results from the Scottish National Health Service. 

The Astra-Zeneca vaccine has been 94% effective in reducing hospitalizations so far compared with the Pfizer vaccine, which has been 85% effective. 

This reversal of efficacy rankings in a real-world observation simply emphasizes that both vaccines are great. 

The most important number of all to remember is that in the thousands and thousands of trial participants who received any of the vaccines there were no COVID deaths and almost no hospitalizations for COVID.

So when you have finally managed to find your vaccine appointment after refreshing the sign-up page a hundred times and been booked four weeks hence, don’t worry about which vaccine you will get. Just pick the one with the smallest needle.

 

James Shepherd, MD PhD, lives in Sharon and is an Infectious Disease physician and epidemiologist who is on the faculty of the Yale University School of Medicine.

Latest News

Connecticut’s long lost Western Reserve

Alex DuBois presented a lecture Saturday, April 13.

Leila Hawken

SHARON — Horace Greeley’s advice to the young man may have been valid later in the 19th century, but at the dawn of that century, when area families contemplated going west to the uncharted Western Reserve, mapped as “New Connecticut,” the going was not for the faint of heart.

During a talk titled, “To Certain Western Lands: Connecticut Stories from the Western Reserve,” Alex DuBois, Curator of Collections at the Litchfield Historical Society, described the realities faced by those who ventured west, leaving New England for a variety of reasons. The lecture was presented by the Sharon Historical Society on Saturday, April 13, following its annual meeting and election of officers.

Keep ReadingShow less
North Canaan budget heads to hearing

NORTH CANAAN — The Board of Finance has sent the 2024-25 spending plans to public hearing scheduled for May 15 at 7 p.m. in Town Hall.

During the board’s April 10 meeting, one change was made to the municipal spending proposal. The Housatonic River Commission’s request for $400 was approved and added to the town budget. Salary negotiations with the highway department remain ongoing, which may lead to another adjustment.

Keep ReadingShow less
Students glimpse into professions at Career Day

Professionals shared insights with Salisbury Central School students on Career Day, April 12.

Patrick L. Sullivan

LAKEVILLE — It started to rain Friday afternoon, April 12 outside the lower building at Salisbury Central School.

This did not make any visible difference to the group of eighth grade students visiting with Salisbury Resident State Trooper Will Veras and Department of Energy and Environmental Conservation officer Ed Norton.

Keep ReadingShow less
Selectmen discuss Community Center lease

SHARON — Making steady progress toward developing a lease arrangement with the Sharon Housing Trust to develop the former Community Center building into four units of affordable housing, the Board of Selectmen discussed finalizing a lease draft at their regular meeting on Tuesday, April 9.

First Selectman Casey Flanagan reported that an attorney specializing in real estate law at the firm of Cramer and Anderson had reviewed a draft of the lease and offered two amendments. The Housing Trust had reviewed those amendments and had recently made small adjustments. Still being discussed is the term of the lease, whether 99 years or 75 years. Also included in the lease is a provision that In the event that the Housing Trust should dissolve before the lease ends, the property would revert to the town.

Keep ReadingShow less